Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yifu Ma"'
Autor:
Yingying Xu MS, Yuehong Kong MS, Yifu Ma MS, Meiling Xu MS, Jiabao Yang MS, Junjun Zhang PhD, Rongzheng Chen MS, Guangqiang Chen MS, Zhihui Hong MS, Xiangrong Zhao MS, Chenyang Zhang MS, Pengfei Xing MS, Liyuan Zhang MD, Peifeng Zhao MS
Publikováno v:
Technology in Cancer Research & Treatment, Vol 23 (2024)
Objective: The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options. The PRaG regimen, which comprised of hypofractionated radiotherapy, programmed cell death-1 (PD-1)
Externí odkaz:
https://doaj.org/article/dc633d6da4714a2380fa6fc73b094b68
Autor:
Chenfeng Han, Minmin Ge, Pengfei Xing, Tian Xia, Cangang Zhang, Kaili Ma, Yifu Ma, Shicheng Li, Wenhui Li, Xiaowei Liu, Baojun Zhang, Liyuan Zhang, Lianjun Zhang
Publikováno v:
Cell Death and Disease, Vol 15, Iss 2, Pp 1-13 (2024)
Abstract Cancer cells develop multiple strategies to evade T cell-mediated killing. On one hand, cancer cells may preferentially rely on certain amino acids for rapid growth and metastasis. On the other hand, sufficient nutrient availability and upta
Externí odkaz:
https://doaj.org/article/93f2d9c74fd6466b8e1a853bbafc19e7
Autor:
Yong Peng, Hong Zhang, Junjun Zhang, Liyuan Zhang, Pengfei Xing, Yuehong Kong, Rongzheng Chen, Meiling Xu, Guangqiang Chen, Zhihui Hong, Xiaoxiao Dai, Yifu Ma, Xiangrong Zhao, Chenyang Zhang
Publikováno v:
BMJ Open, Vol 14, Iss 3 (2024)
Introduction The PRaG regimen, which consists of hypofractionated radiotherapy combined with a programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor and granulocyte-macrophage colony stimulating factor (GM-CSF), has been demon
Externí odkaz:
https://doaj.org/article/ef1743c3427446bca18e3314d58222c7
Autor:
Hao Wu, Ping Zhu, Yixiao Xia, Yifu Ma, Junyao Ding, Huasong Gou, Qiang Zhang, Sen Yang, Gaohui Wu
Publikováno v:
Nanomaterials, Vol 14, Iss 7, p 640 (2024)
Diamond/aluminum composites have attracted significant attention as novel thermal management materials, with their interfacial bonding state and configuration playing a crucial role in determining their thermal conductivity and mechanical properties.
Externí odkaz:
https://doaj.org/article/68e884c3ac194511996736cf6f0916d9
Autor:
Hong Xu, Zhihui Hong, Meiling Xu, Yuehong Kong, Yifu Ma, Chanchan Shan, Pengfei Xing, Liyuan Zhang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Patients with metastatic gastric cancer had limited treatments and often had a somber prognosis, especially when patients were unable to tolerate high-intensity cytotoxic treatment due to poor physical condition or organ dysfunction after the failure
Externí odkaz:
https://doaj.org/article/dd4fffa911b94bb78c3ba1b138f1fa28
Autor:
Yuehong Kong, Xiangrong Zhao, Meiling Xu, Jie Pan, Yifu Ma, Li Zou, Qiliang Peng, Junjun Zhang, Cunjin Su, Zhi Xu, Wei Zhou, Yong Peng, Jiabao Yang, Chengliang Zhou, Yujia Li, Qiuchen Guo, Guangqiang Chen, Hongya Wu, Pengfei Xing, Liyuan Zhang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Patients with metastatic cancer refractory to standard systemic therapies have a poor prognosis and few therapeutic options. Radiotherapy can shape the tumor microenvironment (TME) by inducing immunogenic cell death and promoting tumor recognition by
Externí odkaz:
https://doaj.org/article/911ad0064556408ca97b2ef462dda48b
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Background Nearly 50% of new gastric cancer cases and gastric cancer-related deaths worldwide occur in China. No global consensus has been reached about the optimal management of locally advanced gastric cancer. Although the Guidelines for t
Externí odkaz:
https://doaj.org/article/74bc1e76a2cf4176964dd3e6f3691194
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1) have been approved for a variety of malignant tumors and are widely used to treat patients with metastatic disease. Howev
Externí odkaz:
https://doaj.org/article/d02819f10e1841a3a57b8c573854f69a
Autor:
Pengfei Xing, Jiabao Yang, Yuehong Kong, Meiling Xu, Jian Wang, Jianshe Wang, Yifu Ma, Liyuan Zhang
Publikováno v:
Journal of Clinical Oncology. 40:2609-2609
2609 Background: It’s been widely recognized that T cells play an essential role in immunotherapy of malignant tumors. Notably, in our previous PRaG trial, we observed that T cell decreasing occurred in some patients with advanced refractory solid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a55d007ac2f539656634eab7132ff956
https://doi.org/10.1200/jco.2022.40.16_suppl.2609
https://doi.org/10.1200/jco.2022.40.16_suppl.2609
Publikováno v:
Journal of Clinical Oncology. 40:e15561-e15561
e15561 Background: Immunotherapy has improved outcomes for metastatic colorectal cancer(mCRC) patients with MSI-H/dMMR but has not been effective in MSS/pMMR tumors, which comprise 95% of mCRC. In metastatic cancers, radiotherapy can be used as a loc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96e13b6964ac6504f3a924c45f7d9780
https://doi.org/10.1200/jco.2022.40.16_suppl.e15561
https://doi.org/10.1200/jco.2022.40.16_suppl.e15561